Security Snapshot

Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) Institutional Ownership

CUSIP: 14161W105

13F Institutional Holders and Ownership History from Q1 2018 to Q1 2026

Latest Period

Q1 2026

Institutions Reporting

58

Shares (Excl. Options)

17,205,644

Price

$1.05

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Type / Class
Equity / Common Stock, par value $0.0001
Symbol
CDLX on Nasdaq
Shares outstanding
53,041,500
Price per share
$0.91
All holders as of 31 Mar 2026
Q1 2026
Total 13F shares
17,205,644
Total reported value
$18,063,400
% of total 13F portfolios
0%
Share change
-3,072,633
Value change
-$3,449,687
Number of holders
58
Price from insider filings
$0.91
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Quick Takeaways

  • CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 is tracked under CUSIP 14161W105.
  • 58 institutions reported positions in Q1 2026.
  • 3 significant owners is listed from Schedule 13D/13G reporting.

What Changed

  • Holder count moved from 69 to 58 between Q4 2025 and Q1 2026.
  • Reported value moved from $25,092,582 to $18,063,400.

Why This Matters

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 58 institutions filings for Q1 2026.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 14161W105?
CUSIP 14161W105 identifies CDLX - Cardlytics, Inc. - Common Stock, par value $0.0001 in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q1 2026 holders report and the ownership history table below.

Significant Owners of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
CAS Investment Partners, LLC 9.8% -11% $10,656,037 -$854,463 5,198,067 -7.4% CAS Investment Partners, LLC 19 Aug 2025
VANGUARD GROUP INC 4.6% $3,975,815 2,416,909 The Vanguard Group 30 Jun 2025
BlackRock, Inc. 2.1% $1,810,565 1,098,977 BlackRock, Inc. 30 Jun 2025

As of 31 Mar 2026, 58 institutional investors reported holding 17,205,644 shares of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX). This represents 32% of the company’s total 53,041,500 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) together control 32% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
CAS Investment Partners, LLC 9.8% 5,198,067 0% 0.31% $5,457,970
VANGUARD CAPITAL MANAGEMENT LLC 3.9% 2,063,367 0% 0% $2,166,535
683 Capital Management, LLC 2.7% 1,450,000 +3.6% 0.14% $1,522,500
KPS Global Asset Management UK Ltd 2.3% 1,218,830 0% 0.21% $1,279,772
WORLDLY PARTNERS MANAGEMENT, LLC 2.2% 1,157,989 0% 1% $1,215,888
BlackRock, Inc. 1.9% 990,629 +2.5% 0% $1,040,161
RBF Capital, LLC 1.5% 800,103 0% 0.04% $840,108
GEODE CAPITAL MANAGEMENT, LLC 1.4% 734,232 +12% 0% $771,164
Quinn Opportunity Partners LLC 0.87% 462,402 0% 0.03% $485,522
LPL Financial LLC 0.82% 437,412 -1.8% 0% $459,283
VANGUARD FIDUCIARY TRUST CO 0.61% 324,700 0% 0% $340,935
GSA CAPITAL PARTNERS LLP 0.5% 263,311 -44% 0.02% $276,000
STATE STREET CORP 0.43% 227,731 0% 0% $239,118
UBS Group AG 0.4% 213,265 +15% 0% $223,928
VANGUARD PORTFOLIO MANAGEMENT LLC 0.32% 172,195 0% 0% $180,805
Invesco Ltd. 0.32% 172,008 +1.1% 0% $180,608
HRT FINANCIAL LP 0.28% 146,395 0% $153,000
RAYMOND JAMES FINANCIAL INC 0.27% 143,185 -12% 0% $150,344
RENAISSANCE TECHNOLOGIES LLC 0.21% 112,500 +108% 0% $118,125
NORTHERN TRUST CORP 0.2% 108,455 -3% 0% $113,878
BROWN ADVISORY INC 0.2% 103,828 -3.5% 0% $109,020
BRIDGEWAY CAPITAL MANAGEMENT, LLC 0.14% 75,758 0% 0% $79,546
SIMPLEX TRADING, LLC 0.13% 69,396 -63% 0% $72,865
MILLENNIUM MANAGEMENT LLC 0.12% 65,556 -74% 0% $68,834
GOLDMAN SACHS GROUP INC 0.12% 61,720 -43% 0% $64,806

Institutional Holders of Cardlytics, Inc. - Common Stock, par value $0.0001 (CDLX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q1 17,205,644 $18,063,400 -$3,449,687 $1.05 58
2025 Q4 21,819,398 $25,092,582 -$1,926,794 $1.15 69
2025 Q3 22,781,399 $55,357,566 -$1,193,667 $2.43 81
2025 Q2 24,551,816 $40,388,162 -$6,876,388 $1.64 87
2025 Q1 28,581,930 $52,019,284 -$5,385,568 $1.82 104
2024 Q4 30,318,387 $112,466,107 -$2,088,576 $3.71 105
2024 Q3 30,794,820 $98,563,618 -$20,795,943 $3.20 109
2024 Q2 33,695,414 $276,632,711 -$28,175,400 $8.21 123
2024 Q1 35,620,190 $516,145,298 +$96,938,383 $14.49 141
2023 Q4 29,212,104 $269,093,210 +$5,557,027 $9.21 122
2023 Q3 28,041,297 $463,142,226 +$17,744,620 $16.50 111
2023 Q2 27,412,381 $173,379,558 -$8,554,891 $6.32 107
2023 Q1 28,654,397 $97,285,032 -$6,579,840 $3.40 100
2022 Q4 29,783,293 $172,154,817 -$28,548,438 $5.78 120
2022 Q3 31,554,421 $296,615,241 -$30,189,534 $9.40 119
2022 Q2 31,596,179 $705,114,664 -$47,941,923 $22.31 129
2022 Q1 33,306,573 $1,831,644,508 +$20,984,402 $54.98 148
2021 Q4 32,869,535 $2,172,578,259 +$79,885,779 $66.09 156
2021 Q3 31,254,515 $2,624,187,470 -$77,766,844 $83.94 162
2021 Q2 31,402,934 $3,990,653,437 +$126,270,154 $126.93 189
2021 Q1 29,846,728 $3,274,240,688 +$271,523,652 $109.70 199
2020 Q4 27,784,592 $3,965,954,154 +$70,956,802 $142.77 194
2020 Q3 26,692,394 $1,883,241,294 +$112,252,889 $70.57 162
2020 Q2 25,018,920 $1,750,601,005 +$226,035,991 $69.98 164
2020 Q1 22,440,998 $784,589,581 -$47,809,544 $34.96 141
2019 Q4 23,008,936 $1,446,322,852 +$109,382,347 $62.86 154
2019 Q3 21,246,669 $712,189,095 +$88,173,279 $33.52 117
2019 Q2 19,154,562 $497,359,320 +$81,154,271 $25.98 79
2019 Q1 16,284,415 $269,598,973 +$7,820,714 $16.54 62
2018 Q4 16,111,197 $174,481,975 +$5,332,809 $10.83 61
2018 Q3 11,931,477 $298,164,482 +$47,426,352 $25.04 59
2018 Q2 10,063,300 $217,430,809 +$11,913,905 $21.76 52
2018 Q1 9,791,394 $141,747,708 +$141,747,708 $14.63 51
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Here you can make detailed settings or revoke your consent (in part if necessary) with effect for the future. For further information, please refer to our Privacy Policy .